Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Dose-Response Efficacy and Safety Study of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD) Who Are Incomplete Responders to a Proton Pump Inhibitor (PPI)

NCT00978016 is registered in ClinicalTrials.gov with XenoPort, Inc. as lead sponsor.

NCT NCT00978016
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00978016 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Dose-Response Efficacy and Safety Study of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD) Who Are Incomplete Responders to a Proton Pump Inhibitor (PPI)
Lead sponsor
XenoPort, Inc.
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2009
Completion date
December 31, 2010
Enrollment
460 (actual)
Sites
64

Conditions

As the registry lists them; a condition with its own page is linked.

gastroesophageal reflux disease